SNU-601 Cells

The SNU-601 cell line is derived from a poorly differentiated human gastric carcinoma and is widely utilized in gastric cancer research. This cell line serves as an important model for investigating the molecular and cellular mechanisms underlying gastric adenocarcinoma, which is a prevalent and often aggressive form of stomach cancer. SNU-601 cells are valuable for studying the genetic and epigenetic alterations associated with gastric cancer, as well as for testing the efficacy of potential therapeutic agents. SNU-601 cells exhibit an epithelial morphology and express markers characteristic of gastric carcinoma, including cytokeratins and carcinoembryonic antigen (CEA). They harbor genetic alterations commonly found in gastric cancer, such as mutations in oncogenes and tumor suppressor genes like TP53. Researchers use SNU-601 cells to explore key signaling pathways involved in gastric cancer progression, such as the PI3K/Akt, Wnt/β-catenin, and MAPK pathways. These cells are also employed in high-throughput drug screening assays and preclinical testing of chemotherapeutic agents, targeted therapies, and combination treatments. Additionally, SNU-601 cells are utilized to study mechanisms of drug resistance and to develop strategies to overcome it. The relevance of the SNU-601 cell line in gastric cancer research underscores its importance in advancing our understanding of this malignancy and in developing more effective treatments for gastric cancer patients.